The European Medicines Agency review of entrectinib for the treatment of adult or paediatric patients with solid tumours who have a neurotrophic tyrosine receptor kinase gene fusions and adult patients with non-small-cell lung cancer harbouring ROS1 rearrangements-Reference-Cited by-同舟云学术

The European Medicines Agency review of entrectinib for the treatment of adult or paediatric patients with solid tumours who have a neurotrophic tyrosine receptor kinase gene fusions and adult patients with non-small-cell lung cancer harbouring ROS1 rearrangements

Published:2021-04 Issue:2 Volume:6 Page:100087
ISSN:2059-7029
Container-title:ESMO Open
language:en
Short-container-title:ESMO Open

Author:

Delgado J.,Pean E.,Melchiorri D.,Migali C.,Josephson F.,Enzmann H.,Pignatti F.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference16 articles.

1. Emerging targeted therapy for tumors with NTRK fusion proteins;Kheder;Clin Cancer Res,2018

2. The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma;Wu;Nat Genet,2014

3. The landscape of kinase fusions in cancer;Stransky;Nat Commun,2014

4. How I treat NTRK gene fusion-positive cancers;Lassen;ESMO Open,2019

5. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children;Drilon;N Engl J Med,2018

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The rapidly changing field of predictive biomarkers of non-small cell lung cancer;Pathology and Oncology Research;2024-06-17

2. Optimizing Entrectinib Nanosuspension: Quality by Design for Enhanced Oral Bioavailability and Minimized Fast-Fed Variability;BioNanoScience;2024-05-29

3. Perioperative and palliative systemic treatments for biliary tract cancer;Therapeutic Advances in Medical Oncology;2024-01

4. Comprehensive Review of ROS1 Tyrosine Kinase Inhibitors-Classified by Structural Designs and Mutation Spectrum (Solvent Front Mutation [G2032R] and Central β-Sheet 6 [Cβ6] Mutation [L2086F]);Journal of Thoracic Oncology;2023-12

5. Entrectinib for NTRK Fusion-Positive Metastatic Melanoma Progressing on Combined PD-1 and CTLA-4 Inhibition: A Case Report;Case Reports in Oncology;2023-11-24